NasdaqGS:AMGNBiotechs
Amgen Drops Eczema Drug Pact As Investors Weigh R&D Focus And Valuation
Amgen (NasdaqGS:AMGN) has ended its collaboration with Kyowa Kirin on the eczema drug rocatinlimab.
Rights to develop and commercialize rocatinlimab have been returned to Kyowa Kirin.
The exit is tied to Amgen’s internal portfolio prioritization decisions.
For you as an investor, this move sits at the intersection of biotech R&D risk and portfolio concentration. Amgen is a large biopharmaceutical company with exposure to areas such as inflammation, oncology, and cardiovascular disease, and...